HCVDRUGS.COM
HEPATITIS C NEW DRUG PIPELINE - TEXT
http://www.hcvdrugs.com Copyright hcvdrugs.com, all rights reserved
Updated 15 June 2011
Company Drug Development Phase
Combinations of Drugs That Directly Target The Hepatitis C Virus
Vertex Telaprevir (VX-950) Protease Inhibitor plus VX-222 Non-nucleoside Polymerase inhibitor w&wo Ribavirin and peginterferon Phase 2
Bristol-Myers Squibb - BMS-790052 NS5A Inhibitor plus BMS-650032 Protease Inhibitor w&wo Ribavirin and peginterferon Phase 2
Gilead GS 9190 NN Polymerase Inhibitor plus GS 9256 Protease Inhibitor w&wo Ribavirin and peginterferon Phase 2
Bristol-Myers Squibb / Pharmasset BMS-790052 NS5A inhibitor plus PSI-7792 Nucleotide Polymerase inhib. w&wo Ribavirin Phase 2
Boehringer Ingelheim BI 201335 Protease Inhibitor plus BI 207127 Polymerase inhib. w&wo Ribavirin Phase 1
Idenix IDX184 Nucleoside Polymerase Inhibitor plus IDX320 Protease Inhibitor Phase 1 Halted
Hoffmann-La Roche R7128 (RO5024048) Nucleoside Polymerase Inhibitor plus ITMN-191 R7227 (RO5190591) Protease inhibitor Phase 1
Pharmasset PSI-7977 a pyrimidine and PSI-938 a purine nucleotide analog polymerase inhibitors Phase 1
Drugs That Directly Target The Hepatitis C Virus
Vertex Incivek (Telaprevir VX-950) Protease Inhibitor Approved
Vertex VX-222 Non-nucleoside Polymerase inhibitor (from ViroChem Pharma) Phase 2
Vertex VX-985 Protease Inhibitor Phase 1
Vertex / Alios ALS-2200 HCV NS5B polymerase inhib. Pre Clinical
Vertex / Alios ALS-2158 HCV NS5B polymerase inhib. Pre Clinical
Merck Victrelis (Boceprevir SCH503034) Protease inhibitor Approved
Merck Vaniprevir MK-7009 protease inhibitor Phase 2
Sirna Therapeutics (aquired by Merck) SIRNA-034 RNAi RNA interference Pre Clinical
Isis / Merck MK-0608 nucleoside polymerase inhib. Phase 1
Intermune / Roche Protease inhibitor ITMN-191 R7227 (RO5190591) Phase 2
Intermune 2nd Gen. Protease inhibitor Pre Clinical
Roche / Pharmasset R7128 (RO5024048) nucleoside polymerase inhibitor Phase 2
Roche / Ligand (Metabasis) RG7348 nucleoside Phase 1
Roche / Medivir HCV polymerase inhibitor R & D
Medivir / Tibotec / JnJ TMC435 Protease inhibitor Phase 3
Medivir / Tibotec TMC649128 Nucleoside NS5B polymerase inhibitor Phase 1
Pfizer PF-868554 Non-Nuc Polymerase inhibitor Phase 2
Pfizer PF-4878691 Phase 1
Tacere Bio / Benitec / Pfizer RNA interference TT033 Pre Clinical
Boehringer Ingelheim BI 201335 protease inhibitor Phase 3
Boehringer Ingelheim BI 207127 Polymerase inhib. Phase 1
Intercell / Novartis IC41 Therapeutic Vacccine Phase 2
Bristol-Myers Squibb BMS-790052 NS5A Inhibitor Phase 2
Bristol-Myers Squibb BMS-791325 Protease inhibitor Phase 1
Bristol-Myers Squibb BMS-650032 NS3 Inhibitor Phase 2
Bristol-Myers Squibb BMS-824393 Phase 2
Anadys ANA598 Polymerase inhib Phase 2
ViroChem Pharma (acquired by Vertex) VCH-759 Non nuc Polymerase inhib Phase 1 backup for VX-222
Globeimmune GI 5005 Therapeutic Vaccine Phase 2
iTherX (formerly Immusol) ITX5061 Entry Inhibitor Phase 2
iTherX ITX4520 Entry Inhibitor Pre Clinical
iTherX Viral Envelop & Host Cell Receptor Entry Inhibitors R & D
Idenix IDX184 Nucleoside Polymerase Inhibitor Phase 2
Idenix Protease Inhibitor IDX320 Phase 1 Halted
Idenix Non-Nuc Polymerase Inhibitor IDX375 Phase 1
Idenix NS5A Inhibitors Pre Clinical
Abbott A-837093 Non-nuc polymerase inhib Phase 1
Gilead GS 9190 non-nuc polymerase inhibitor Phase 2
Gilead GS 9256 Protease Inhibitor Phase 2
Gilead Protease polymerase inhib R & D
Achillion Gilead ACH-1095 NS4A Antagonist Pre Clinical
Achillion ACH-1625 Protease inhibitor Phase 2
Achillion ACH-2684 Protease inhibitor Pre Clinical
Achillion ACH-2928 NS5A inhibitor Pre Clinical
Presidio PPI-461 NS5A inhibitor Phase 1
Presidio PPI-1301 NS5A inhibitor Pre Clinical
Aethlon Medical Hemopurifier Phase 1
Transgene TG4040 (MVA-HCV) Therapeutic Vaccine Phase 2
ChronTech Pharma (Tripep) / Inovio Therapeutic Vaccine Chronvac-C Phase 2
Arrow Therapeutics (aquired by AstraZeneca) AZD7295 NS5A inhibitor Phase 2
Arrow Therapeutics Polymerase Inhibitor Pre Clinical
Arrow Therapeutics Protease Inhibitor R & D
U of Mass. Med School MBL-HCV1 human monoclonal antibody Phase 2
Eiger BioPharmaceuticals Clemizole NS4B-RNA Binding Inhibitor Phase 1
Eiger BioPharmaceuticals Amphipathic Helix Inhibitors Pre Clinical
Santaris Pharma SPC3649 Locked Nucleic Acid mRNA122 inhibitor Phase 1
GENimmune (subsidiary of Innogenetics) GNI-103 – Therapeutic vaccine Pre Clinical
GENimmune GNI-104 - monoclonal antibodie E1 protein R & D
ChemDiv / IDialog ID-12 small molecule Pre Clinical
GlaxoSmithKline (Genelabs) GSK625433 Polymerase Inhibitor Phase 1
GlaxoSmithKline Non-nucleoside & nucleoside polymerase inhib. Pre Clinical
GenPhar Vaccine Pre Clinical
Abbott / Enanta ABT-450 Protease inhib Phase 2
Abbott ABT-072 Non-Nucleoside Polymerase Inhibitor Phase 2
Abbott ABT-333 Non-Nucleoside Polymerase Inhibitor Phase 2
Pharmasset PSI-7977 nucleoside polymerase inhib. Phase 2
Inhibitex INX-189 Polymerase inhibitor Phase 1 Complete
Pharmasset PSI-938 nucleoside polymerase inhib. Phase 1
Enanta EDP-239 NS5A Polymerase Inhibitor Pre Clinical
Enanta Cyclophilin binder R & D
Dynavax Immunostimulatory sequences SD-101 Type C TLR9 agonist Phase 1
Compass Biotechnologies (Cyplasin / C-Pharma) VLP vaccine Phase 1
Phenomix protease inhibitor Pre Clinical
Samaritan Pharmaceuticals SP-30 entry inhibitor Pre Clinical
Avila Therapeutics AVL-181 protease inhibitor Pre Clinical
Avila Therapeutics AVL-192 protease inhibitor Pre Clinical
Altor BioScience Soluble T-cell Antigen Receptor Pre Clinical
Arisyn Therapeutics ATI-0810 (Formerly PG301029) RNA and protein production inhibitor Pre Clinical
Progenics PRO 206 entry inhibitor Pre Clinical
BioWest (Migenix) N-nucleoside Poly inhib Pre Clinical inactive
PTC / Merck (Schering) IRES inhib Pre Clinical
Vertex Helicase inhibitor R & D
Cetek small molecule R & D
Itherx (Immusol) / Novartis ITX2155 l R & D
Argos Therapeutics Therapeutic Vaccine R & D
Tibotec Polymerase inhib. R & D
Regulus Therapeutics (Alnylam / Isis) GlaxoSmithKline microRNA antagonism of miR-122 R & D
CombiMatrix RNAi R & D
Boehringer Ingelheim / Biota Nucleoside analogues R & D
BioLeap ???? R & D
Biotron targeting HCV-p7 R & D
NanoViricides HepaCide-I R & D
Hanall Antihepatitis agents R & D
Astex Therapeutics Enzyme Inhibitor R & D
Avexa / TargetDrug replication inhib. R & D
StemCells Inc HCV resistant Human liver engrafting cells R & D
Vertex VX-500 protease inhibitor Phase 1
Vertex VX-813 2nd gen protease inhibitor Pre Clinical
Chiron / CSL Therapeutic Vaccine CSL123 Phase 2
Biocryst Polymerase inhibitor Pre Clinical
ViRex Medical Hepavaxx C Therapeutic Vaccine Pre Clinical
Genmab HuMax-HepC antibody Pre Clinical
Protiva Biotherapeutics siRNA Pre Clinical
Phenomix PHX1766 protease inhibitor Phase 1
Immune Modifiers and Other Non-specific Drugs
Human Genome Sciences ZALBIN (Albuferon albinterferon alfa-2b) (interferon / albuminfusion) Phase 3
SciClone Pharma SCV-07 immunomodulator - STAT3 signaling inhibitor Phase 2
Migenix MX3235 Celgosivir alpha-glucosidase I inhibitor Phase 2 inactive
Intarcia Omega Interferon Phase 2
NABI Polyclonal antibody Civacir Phase 2
Romark Laboratories Alinia (Nitazoxanide) Phase 3
Biolex / OctoPlus Locteron controlled release interferon Phase 2
Kemin Pharma KPE02001003 Phase 2
Kemin Pharma KPE00001113 R & D
VioQuest Pharmaceuticals Lenocta (sodium stibogluconate SSG) Phase 2
Conatus CTS-1027 MMP inhibitor Phase 2
Jenkin JKB-122 antiinflammatory Phase 2
Oklahoma University Health Sciences Center Fluvastatin Phase 2
Antipodean Mito-Q antiinflammatory Phase 2 Complete
Phynova PYN17 antiviral anti-inflammatory anti-fibrotic Phase 2
Canopus CB5300 antiviral Phase 2
Medtronic continuous subcutaneous interferon external pump infusion system Phase 2
Flamel Technologies Medusa polymer controled release Interferon alpha-2b XL Phase 2
Phynova PYN18 anti viral plant extract Pre Clinical
Can-Fite CF102 antiinflammatory Phase 2
Biotron BIT225 Phase 1
Peregrine Pharm Bavituximab Phase 2
Amarillo Bioscience / CytoPharm Low Dose Oral Interferon Phase 2
Bristol-Myers Squibb (was owned by ZymoGenetics) PEG-Interferon lambda Phase 2
Novelos NOV-205 immunomodulating and antiinflammatory Phase 2
Scynexis SCY-635 cyclophilin inhibitor Phase 1
Idera IMO-2125 TLR9 Agonist Phase 1
Anadys ANA773 TLR7 agonist Phase 1
Novartis / Debiopharm Debio 025 Cyclophilin Inhibitor Phase 3
Bristol-Myers Squibb / Ono MDX-1106 (ONO-4538) anti-PD1 Phase 1
Cytheris CYT107 Interleukin-7 Phase 2
Cubist CB-183872 Protein therapeutic - Formerly IB657 (Illumigen Biosciences) Pre Clinical
REPLICor REP 9C broad-spectrum entry inhibitor Phase 1
Nautilus Oral Belerofon R & D
Anadys AN 025-1 R & D
Genodyssee GEA007.1 IFN alpha variant Pre Clinical
Alios BioPharma Glycoferon Pre Clinical
SciClone Pharma / Sigmatau Zadaxin - thymalfasin Phase 3
Bioenvision Suvus Phase 2
Enzo Biochem Immune Regulator ECH18 Phase 1
Immunomedics IMMU 105 Phase 1
Transition Therapeutics IET Interferon Enhancing Therapy Phase 2
HCVDRUGS.COM